Five things for pharma marketers to know: Friday, September 1, 2017

600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar

from Most popular articles from Medical Marketing and Media http://ift.tt/2wpyvaG